SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001737287-23-000017
Filing Date
2023-02-28
Accepted
2023-02-28 16:07:31
Documents
14
Period of Report
2023-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K allo-20230228.htm   iXBRL 8-K 34434
2 EX-99.1 allo-20230228xexx9912022pr.htm EX-99.1 72536
6 g725933allogenea06a.jpg GRAPHIC 7772
  Complete submission text file 0001737287-23-000017.txt   267325

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20230228.xsd EX-101.SCH 1987
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20230228_lab.xml EX-101.LAB 24132
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20230228_pre.xml EX-101.PRE 12593
8 EXTRACTED XBRL INSTANCE DOCUMENT allo-20230228_htm.xml XML 10862
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 23685197
SIC: 2836 Biological Products, (No Diagnostic Substances)